tbuckley/cabot-search huggingface dataset:
Acute Renal Failure after the Administration of Iopanoic Acid as a Cholecystographic Agent
Authors: C. O. Canales, G. H. Smith, J. C. Robinson, A. R. Remmers, H. E. Sarles
Journal: New England Journal of Medicine (1969)

ACUTE renal failure after the ingestion of iopanoic acid† has previously been reported.1 However, from this report it is difficult to implicate iopanoic acid as the sole cause of renal injury, for each of the patients had received other cholecystographic agents. One of these agents, bunamiodyl,‡ has been associated with numerous cases of acute renal failure.2 3 4 Of the four cases of acute renal failure associated with the ingestion of iopanoic acid reported below, doses exceeding those recommended by the manufacturer§ were given in three. It is common practice to administer larger amounts of this cholecystographic agent when the gallbladder fails . . .
Duchenne muscular dystrophy: relevant paper was not included
Authors: R. A Smith, R. S Phillips
Journal: BMJ (2001)

The "Scared Straight" programme in the United States is another popular and politically attractive programme, in which high school students are shown life in prison in order to scare them out of a life of crime.5 Systematic reviews of the programme have shown adverse outcomes for the subjects.We have been alarmed to learn that a variant of this programme has been introduced into the United Kingdom, and we have asked the Home Office to discourage it from our schools (JM, personal communication).Unanswered questions remain about many aspects of public policy, particularly in criminal justice and community safety-the effectiveness of closed circuit television (CCTV), street lighting, and police on the beat, and of boot camps versus adventure camps.Many of these could be answered best through properly constructed randomised controlled trials.
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity
Authors: Chenyi Yang, Cynthia A. Boyson, Maurizio Di Liberto, Xiangao Huang, Jeffrey Hannah, David C. Dorn, Malcolm A.S. Moore, Selina Chen-Kiang, Pengbo Zhou
Journal: Cancer Research (2015)

Cyclin-dependent kinase (CDK)4 and CDK6 are frequently overexpressed or hyperactivated in human cancers. Targeting CDK4/CDK6 in combination with cytotoxic killing therefore represents a rational approach to cancer therapy. By selective inhibition of CDK4/CDK6 with PD 0332991, which leads to early G1 arrest and synchronous S-phase entry upon release of the G1 block, we have developed a novel strategy to prime acute myeloid leukemia (AML) cells for cytotoxic killing by cytarabine (Ara-C). This sensitization is achieved in part through enrichment of S-phase cells, which maximizes the AML populations for Ara-C incorporation into replicating DNA to elicit DNA damage. Moreover, PD 0332991 triggered apoptosis of AML cells through inhibition of the homeobox (HOX)A9 oncogene expression, reducing the transcription of its target PIM1. Reduced PIM1 synthesis attenuates PIM1-mediated phosphorylation of the proapoptotic BAD and activates BAD-dependent apoptosis. In vivo, timely inhibition of CDK4/CDK6 by PD 0332991 and release profoundly suppresses tumor growth in response to reduced doses of Ara-C in a xenograft AML model. Collectively, these data suggest selective and reversible inhibition of CDK4/CDK6 as an effective means to enhance Ara-C killing of AML cells at reduced doses, which has implications for the treatment of elderly AML patients who are unable to tolerate high-dose Ara-C therapy.
The inhibition of Staphylococcus epidermidis biofilm formation by vancomycin-modified titanium alloy and implications for the treatment of periprosthetic infection
Authors: Valentin Antoci, Christopher S. Adams, Javad Parvizi, Helen M. Davidson, Russell J. Composto, Theresa A. Freeman, Eric Wickstrom, Paul Ducheyne, Donald Jungkind, Irving M. Shapiro, Noreen J. Hickok
Journal: Biomaterials (2008)
Law and Medicine
Authors: John W. McFadden
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ADAPTATION AND INSERTION OF AN ARTIFICIAL EYE; ENUCLEATION, SYMPATHETIC PHENOMENA, ETC.
Authors: WILLIAM B. MEANY
Journal: JAMA (1897)

The exercise of a little care with "troublesome" cases in the taking of a caste—either with dentist wax or with superfine dental plaster-of-paris—of the tissue walls of the orbital cavity resulting from the removal of an eyeball, and the artificial eye to be inserted fashioned on the lines of the "model," may overcome the difficulties complained of by advocates of dangerous substitute proceedings for the benign operation of enucleation. An artificial eye should be fabricated to meet the requirements of the anatomic conformation of the orbital cavity, rather than the adaptation of the tissue walls to a misfit or bespoke eye—which has never been known to vary from its present shape for half a century or thereabouts. By the adoption of this plan of procedure hazardous and unwarrantable "operations" that permit the retention of a portion of the structure of an eyeball that has become or is liable to take
The Value of HRCT and Tc-Depreotide in the Evaluation of Pulmonary Lesions
Authors: Karin Rasmussen, Hans H. Madsen, Finn Rasmussen, Torben R. Rasmussen, Ulrik Baandrup, Hans K. Pilegaard, Ulrik Pedersen, Torben Palshof, Michael Rehling
Journal: Journal of Thoracic Oncology (2006)
Renal and adrenal responses to hypoxemia during angiotensin-converting enzyme inhibition in lambs.
Authors: D N Weismann, J E Herrig, O J McWeeny, N A Ayres, J E Robillard
Journal: Circulation Research (1983)

Chronically catheterized lambs (4-37 days postnatal age) (n =35) were studied to test the hypothesis that the products of angiotensin-converting enzyme activity are involved in renal and adrenal responses to normocapnic hypoxemia in immature lambs.Arterial angiotensin II (from 111.0 ± 38.8 to 71.0 ± 38.8 pg/ml, P < 0.01) and aldosterone (from 128.0 ± 98.0 to 62.1 ± 27.9 pg/ml, P < 0.01) concentrations were significantly decreased and vasopressor responses to angiotensin I were greater than 90% inhibited by continuous intravenous infusion of angiotensin-converting enzyme inhibitor (captopril, 2.5 /ig/kg/min, n =16).Baseline mean arterial pressure (64 ± 14 vs. 78 ± 9 mmHg) and urinary sodium excretion rate (UN 8 V 3.04 ± 2.83 vs. 15.00 ± 20.00 fiEq//min) were significantly (P < 0.05) decreased in captopril-treated lambs vs. control lambs.Baseline arterial plasma renin activity was significantly (P < 0.01) increased in captopril-treated vs. control lambs (8.6 ± 9.0 vs. 100.0± 64.0 ng/ml per hr).Normocapnic hypoxemia (P02 38 ± 6 torr for 30 minutes) during captopril infusion was associated with no significant (P > 0.05) changes in renal hemodynamics and function, including glomerular filtration rate (from 0.34 ± 0.24 to 0.35 ± 0.25 ml/min per g).Urinary prostaglandin E excretion rate (from 0.655 ± 0.703 to 1.310 ± 1.020 ng/min) and adrenal blood flow (from 2.67 ± 1.69 to 6.24 ± 3.73 ml/min per g) increased significantly (P < 0.05) under these conditions.Arterial epinephrine (from 0.11 ± 0.07 to 1.1 ± 1.8 ng/ml), norepinephrine (0.48 ± 0.38 to 3.2 ± 5.4 ng/ml), and arginine vasopressin (from 5.11 ± 2.20 to 10.70 ± 8.61 jiU/ml) also increased significantly (P < 0.05) in response to hypoxemia during angiotensin-converting enzyme inhibition with captopril.None of these responses to hypoxemia were significantly different from that of uninhibited (control) lambs (n=19).In contrast, cortisol response to hypoxemia was significantly (P < 0.05) less in captopril-treated lambs (captopril vs. control, -1.00 ± 1.90 vs. 3.40 ± 3.30 /ig/dl).These data suggest that the products of angiotensin-converting enzyme activity are not important regulators of renal responses to hypoxemia, but may be involved in cortisol responses to normocapnic hypoxemia in immature lambs.(
Blood Quinidine Concentrations as a Guide in the Treatment of Cardiac Arrhythmias
Authors: MAURICE SOKOLOW, A. L. EDGAR
Journal: Circulation (1950)

Blood quinidine determinations by the photofluorometric method were made in 30 patients with auricular fibrillation or flutter in whom conversion to sinus rhythm was attempted. Successful conversion occurred in 82 per cent of the patients, with a mean blood level of 5.9 mg./liter. Vomiting and, in one case, ventricular tachycardia were the most important toxic manifestations. Doses of 0.4 to 0.6 Gm. every two hours for five doses daily were usually adequate to obtain the average conversion blood level. The importance of the quantitative aspects of quinidine therapy and the relation of time, dose and concentration of quinidine in the blood are discussed.
Age at symptom onset and distribution by sex and symptoms in patients sensitized to different allergens
Authors: S. Guerra, L. Allegra, F Blasi, M. Cottini
Journal: Allergy (1998)

The aim of our study was to analyze the clinical features, particularly the age at symptom onset, of allergic subjects (asthma and/or rhinitis) on the basis of the etiologic elements (sensitization to various allergens). We identified a group of monosensitized patients and a group of polysensitized patients. Within these groups, we identified subgroups of subjects monosensitized to one of the five main allergenic mixes (mites, Gramineae, trees, Parietaria, and Artemisia) and five subgroups of patients sensitized nonexclusively, that is, polysensitized, to the same allergens. The comparison between the two groups and among the various subgroups enabled us to conclude that: mono‐ and polysensitized patients present some clinical features so different as to constitute two clearly distinct clinical groups analysis of the clinical features associated with the sensitization to a specific allergen brings us to significantly different conclusions when we consider subgroups of monosensitized or polysensitized patients the parameter “age at symptom onset” shows great heterogeneity among both the mono‐ and the polysensitized subgroups ‐ in particular, the great differences in mean age among the monosensitized subgroups (trees&gt;y4rtemi.s(fl&gt;Pflrie/flria&gt;Gramineae&gt;mites) appear very interesting and are open to various interpretative hypotheses unlike the polysensitized group, in the monosensitized group and subgroups, mean age is similar between men and women and, only for tree‐ and parietaria ‐monosensitive patients, also between asthmatic and rhinitic subjects.
Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma
Authors: G. Jónasson, K‐H. Carlsen, C. Jonasson, P. Mowinckel
Journal: Allergy (2000)

This study is an extended follow‐up for 24 months of a 12‐week trial to study the long‐term clinical efficacy of low‐dose inhaled budesonide (BUD) once or twice daily in children with mild asthma. A total of 122 children (mean age 9.7 years, girls/boys; 42/80) with mild asthma (FEV 1 103.7% of predicted, reversibility in FEV 1 3.5%, and fall in FEV 1 afterexercise 12.2%), not previously treated with inhaled steroids, were included in a double‐blind, randomized, parallel‐group study. The children were treated with inhaled BUD 100 or 200 µg administered via Turbuhaler® once daily in the morning, 100 µg twice daily, or placebo for 27 months. Exercise and methacholine challenges were performed at 3‐month intervals the first year and at 6‐month intervals the second year, in a total of seven visits. A significant dose‐response effect favoring BUD 200 µg daily ( vs 100 µg daily) was found when comparing changes in FEV 1 , FEF 25% , and FEV 50% ; the fall in FEV 1 after an exercise test; and the effect on blood eosinophils. Bronchial hyperreactivity to methacholine decreased significantly on three visits in patients treated with BUD 200 µg daily compared to placebo. Growth rate was not significantly affected except in children aged 7–11 years at baseline after 12 months of treatment. In conclusion, 100 or 200 µg daily of inhaled BUD for 27 months is safe and effective in protecting against exercise‐induced asthma and achieving nearly normal lung function. Baseline lung function was not significantly affected in this group of children with mild asthma.
Reduced response to activated protein C and inherited factor V mis-sense mutation in patients with a history of acute myocardial infarction or essential hypertension
Authors: Th.K. Makris, P.G. Krospl, A.N. Halzizacharias, A.G. Gialeraki, G.P. Anastasiadis, N.V. Dallanis, V.E. Vottens, C.D. Panagiotopoulou, T.E. Mandalaki, M.K. Kyriakidis
Journal: Journal of the American College of Cardiology (1998)
Tissue Necrosis Following Subcutaneous Infiltration with Nor-Epinephrine
Authors: H. P. Greenwald, A. Gootnick, N. M. Luger, J. A. King
Journal: New England Journal of Medicine (1952)

NOR–EPINEPHRINE has recently come into wide use in the treatment of hypotensive states of medical or surgical origin.1 2 3 4 Review of the literature does not reveal any reports of adverse skin reaction, with one exception: Deterling and Apgar5 allude briefly to minor ulceration following the infiltration of tissues with nor-epinephrine. Among the 55 patients who have received nor-epinephrine in this hospital, 2 have recently been observed in whom extensive necrosis developed within forty-eight hours after subcutaneous leakage of nor-epinephrine from an intravenous infusion. The purpose of this report is to warn physicians of this reaction and to suggest an expedient for . . .
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies
Authors: Ramon V. Tiu, Lukasz P. Gondek, Christine L. O'Keefe, Paul Elson, Jungwon Huh, Azim Mohamedali, Austin Kulasekararaj, Anjali S. Advani, Ronald Paquette, Alan F. List, Mikkael A. Sekeres, Michael A. McDevitt, Ghulam J. Mufti, Jaroslaw P. Maciejewski
Journal: Blood (2011)
Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator
Authors: Francesca A. Nicolini, Wilmer W. Nichols, Jawahar L. Mehta, Tom G.P. Saldeen, Richard Schofield, Michael Ross, Denifield W. Player, Gunnar B. Pohl, Christer Mattsson
Journal: Journal of the American College of Cardiology (1992)
Regulation of Very-Low-Density Lipoprotein Receptor in Hypertrophic Rat Heart
Authors: Hiroaki Masuzaki, Hisato Jingami, Naoki Matsuoka, Osamu Nakagawa, Yoshihiro Ogawa, Megumi Mizuno, Yasunao Yoshimasa, Tokuo Yamamoto, Kazuwa Nakao
Journal: Circulation Research (1996)

Abstract To elucidate the regulation of very-low-density lipoprotein (VLDL) receptor, we have studied its gene expression in the heart of spontaneously hypertensive rats–stroke prone (SHR-SP, an animal model for hypertension-induced cardiac hypertrophy) compared with Wistar-Kyoto rats. RNase protection assay showed that ventricular VLDL receptor mRNA falls to 41% of normal levels at 4 weeks, when hypertension is not yet fully developed, and drops further to 14% at 13 weeks, when cardiac hypertrophy is established. Lipoprotein lipase mRNA decreases in parallel with VLDL receptor mRNA. In cultured neonatal rat ventricular cardiomyocytes, VLDL receptor mRNA decreases in parallel with the process of cardiocyte hypertrophy during the 24 hours after treatment with 10 −8 mol/L endothelin-1, falling to 40% of the initial value. These results demonstrate that there is downregulation of VLDL receptor gene expression in cardiac hypertrophy both in vivo and in vitro and suggest that the regulation of the VLDL receptor is possibly linked with the switch in energy substrate from lipid to glucose known to occur in cardiac hypertrophy.
Epicardial Neodymium
Authors: Dietrich Pfeiffer, Rainer Moosdorf, Robert H. Svenson, Laszlo Littmann, Wolfram Grimm, Paul G. Kirchhoff, Berndt Lu¨deritz
Journal: Circulation (1996)

Surgical ablation of ventricular tachycardia (VT) after myocardial infarction has been reported by different endocardial approaches. The ventriculotomy may increase mortality of the procedure.We report on nine patients who suffered from recurrent VT in the late post-myocardial infarction period. Significant stenoses were detected in all patients. The mean left ventricular ejection fraction was 43.1 +/- 8.3%. Left ventricular scar (n = 9) was seen. The mean NYHA class was 2.2 +/- 0.4. Sustained VT (mean cycle length, 293 +/- 52 ms) occurred spontaneously (n = 9) and could be induced reproducibly. Catheter mapping detected a prematurity of -42 +/- 13 ms in six patients. Clinical VT was inducible during surgery in seven patients. Middiastolic potentials were detected from the epicardial surface (n = 3), and premature potentials were found (n = 8 with prematurity of -108 +/- 46 ms). Application of neodymium/yttrium/argon/ garnet (Nd:YAG) laser energy to early epicardial activation terminated the arrhythmia (n = 7). Ventriculotomy was not performed. Seven patients have been free of VT for a mean follow-up period of 17 +/- 11 months; one patient relapsed and was treated with an implantable cardioverter-defibrillator, as was a second patient with inducible VT after surgery.Surgical Nd:YAG laser photocoagulation of VT on the epicardial surface of the heart in post-myocardial infarction patients without ventriculotomy is safe and has a high success rate. At the present time, this method is recommended in patients with sustained and tolerated VT who need bypass surgery. This is the first report on epicardial laser ablation of VT in post-myocardial infarction VT.
Functional changes in the right and left ventricle during development of cardiac hypertrophy and after its regression
Authors: R. Cihak, F. Kolar, V. Pelouch, J. Prochazka, B. Ostadal, J. Widimsky
Journal: Cardiovascular Research (1992)

Objective: The aim was to determine left and right ventricular functional reserves and collagen concentration during the development of cardiac hypertrophy and after its regression. Methods: Two experimental models of cardiac hypertrophy (chronic thyroxine or isoprenaline treatment of adult rats) were compared 24 h and five weeks after the agent was last given. Pressure changes in the left (right) ventricle before and after acute aortic (pulmonary artery) ligation were recorded in open chest anaesthetised animals. The difference in dP/dtmax after and before ligation was regarded as the functional reserve. The total collagen concentration was determined in both ventricles separately by means of hydroxyproline. Results: Left and right ventricular weight increased by 20% and 30% respectively in the two models employed. In the thyroxine treated group, the functional reserve of the left ventricle rose very noticeably, whereas in the isoprenaline treated group it decreased. The right ventricular functional reserve did not differ from that in the controls in either of the two groups. The collagen concentration rose in the left ventricle in the isoprenaline group only. Five weeks after the last administration of the agent, cardiac mass and ventricular function did not differ from the control values in either of the models studied; the only exception was the incomplete regression of left ventricular hypertrophy and persistent structural and functional impairment of the left ventricle in the isoprenaline treated group. Conclusions: Our results indicate that hearts undergoing a comparable degree of experimental hypertrophy may have different functional and structural properties; significant differences were found between the right and left ventricular response. Regression of hypertrophy together with a reversal of ventricular function usually occurs unless the myocardium has received severe structural damage. Cardiovascular Research 1992;26:845–850
The Changed Attitude Toward Hansen's Disease
Authors: Howard N. Morse
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
1000–34 Facilitated Lumen Enlargement by Longitudinal Force Focused Angioplasty
Authors: Sandeep Khurana, Donovan Bakalyar, Theodore Schreiber, Steven Almany, V. Gangadharan, Terry R. Bowers, V.M. Reddy, William W. O’Neill, Robert D. Safian
Journal: Journal of the American College of Cardiology (1995)
EXTENSION APPARATUS FOR FRACTURE OF THE FEMUR
Authors: D. W. Crile
Journal: BMJ (1918)

From recoileotions of a picture of a pa-acoSbal incision i>n a Nbook 0n, Operativre surgery such an incision was tried on one occaston.Fortunately the case was one of ru}ptured omentum wbioh could be dealt with by this route, as neither the spleen nor any other organ could' be easily.approacherd frena 'thiis .dirootton.It is unsoUnd anlatomically.
Defibrillators in general practice.
Authors: C Clyde, A Kerr, A Varghese, C Wilson
Journal: BMJ (1984)

After a successful pilot scheme introduced in 1975, when six portable defibrillators were provided for health centres, an additional 50 defibrillators were provided in February 1982 for general practitioners to use. Between December 1975 and February 1984 defibrillation was attempted in 54 patients who collapsed with clinical cardiac arrest in the presence of general practitioners or less than five minutes before their arrival. A cardiac output was achieved in 32 patients, 28 survived to reach hospital via a mobile coronary care unit, and 22 were discharged alive. Of the 28 admitted to hospital, 24 were found to have myocardial infarction. If all general practitioners carried defibrillators they might make an important dent in the early mortality from myocardial infarction in addition to that achieved by a mobile coronary care unit.